{
    "clinical_study": {
        "@rank": "154909", 
        "acronym": "GARFIELD-VTE", 
        "arm_group": [
            {
                "arm_group_label": "Prospective cohort 1", 
                "description": "In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months."
            }, 
            {
                "arm_group_label": "Prospective cohort 2", 
                "description": "In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The protocol is a large registry to describe acute, sub-acute and extended duration of\n      anticoagulation management, clinical and economic duration of anticoagulation management,\n      clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the\n      real-world setting.\n\n      Main objectives are to clarify the:\n\n        -  treatment related details for acute VTE (either conventional anticoagulation therapy,\n           treatment with a direct oral anti-coagulant or other modalities of treatment)\n\n        -  Rate of early and late symptomatic VTE recurrence\n\n        -  Rate and nature of complications of VTE including post thrombotic syndrome and chronic\n           thromboembolic pulmonary hypertension\n\n        -  Rate of bleeding complications\n\n        -  Rate of all-cause mortality at six months"
        }, 
        "brief_title": "Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Venous Thromboembolism", 
            "Deep Vein Thrombosis", 
            "Pulmonary Embolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Embolism", 
                "Pulmonary Embolism", 
                "Thromboembolism", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "Other objectives are to clarify the additional outcomes of:\n\n        -  Stroke (Measured by number of incidences)\n\n        -  Transient Ishaemic Attack (TIA) (Measured by number on incidences)\n\n        -  ST Elevated Myocardial Infarction (STEMI) (Measured by number of incidences)\n\n        -  Non-ST Elevated Myocardial Infraction (NSTEMI) (Measured by number of incidences)\n\n        -  Unstable Angina (Measured by number of incidences)\n\n        -  Quality of life and patient reported outcomes and costs associated with the management\n           of VTE."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age 18 years and over\n\n          -  Treated first time or recurrent DVT (lower or upper extremity), PE alone or\n             overlapping DVT and PE confirmed by appropriate diagnostic methods (patients must be\n             assessed for eligibility within 30 days of diagnosis)\n\n          -  Patients included with recurrent VTE must have completed treatment for the previous\n             VTE episode\n\n        Exclusion Criteria:\n\n          -  Patients for whom long-term follow-up is not envisaged within the enrolling hospital\n             or the associated primary care physician\n\n          -  Patients participating in an interventional study that dictates treatments, visit\n             frequency, or diagnostic procedures\n\n          -  Patients with only superficial vein thrombosis (SVT)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Sites will be selected at random from a representative list reflecting treatment patterns\n        in each country. Consecutive male and female VTE patients at the randomly selected sited\n        will be included in the registry if they meet the eligibility criteria."
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155491", 
            "org_study_id": "TRI08889"
        }, 
        "intervention_browse": {
            "mesh_term": "Anticoagulants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "venous, thromboembolism, embolism, DVT, Pulmonary Embolism, thrombosis", 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "Global Anticoagulant Registry in the FIELD, Venous thromboembolism Event (GARFIELD-VTE)", 
            "url": "http://www.tri-london.ac.uk/garfield-vte"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Muscle Shoals", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35662"
                }, 
                "name": "Dr Terence Hart"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Global Anticoagulant Registry in the Field Observing Treatment and Outcomes in Patients With Treated Acute Venous Thromboembolic Events in the Real World", 
        "overall_official": {
            "affiliation": "Thrombosis Research Institute", 
            "last_name": "Ajay K Kakkar, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Rate of recurrent symptomatic VTE (DVT and fatal or non-fatal PE)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Frequency, location, severity (classified as major or non-major)", 
                "measure": "Bleeding events", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences.", 
                "measure": "Hospitalisation", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences and severity.", 
                "measure": "Post Thrombotic Syndrome", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences and severity.", 
                "measure": "Chronic thromboembolic pulmonary hypertention", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences.", 
                "measure": "IVC filter placement", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences.", 
                "measure": "Other urgent interventions for VTE", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Estimation of Anticoagulation therapy will be compared to actual total time Anticoagulation therapy was used by patients.", 
                "measure": "Anticoagulation therapy persistence", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Causes of death: PE, stroke, cardiac, cancer-related, other...", 
                "measure": "All cause of mortality", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Will be assessed by frequency of INR monitoring, and number of INR readings taken  before patient achieved optimum range.", 
                "measure": "International Normalised Ratio (INR) Values in Patients treated with Vitamin K Antagonists", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "reference": [
            {
                "PMID": "18296591", 
                "citation": "Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):370-2. doi: 10.1161/ATVBAHA.108.162545. Review. PubMed"
            }, 
            {
                "PMID": "17938798", 
                "citation": "Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756-64. PubMed"
            }, 
            {
                "PMID": "9521222", 
                "citation": "Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998 Mar 23;158(6):585-93."
            }, 
            {
                "PMID": "17296569", 
                "citation": "Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007 Feb;92(2):199-205."
            }, 
            {
                "PMID": "14718318", 
                "citation": "Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004 Jan 12;164(1):17-26. Review."
            }, 
            {
                "PMID": "19222476", 
                "citation": "Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009 May;145(3):286-95. Epub 2009 Feb 13. Review."
            }, 
            {
                "PMID": "10069756", 
                "citation": "Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis. 1998;28 Suppl 3:1-7. Review."
            }, 
            {
                "PMID": "9666534", 
                "citation": "Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med. 1998;3(1):57-60. Review. PubMed"
            }, 
            {
                "PMID": "17032933", 
                "citation": "MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S5-15. PubMed"
            }, 
            {
                "PMID": "15163775", 
                "citation": "Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64."
            }, 
            {
                "PMID": "11157648", 
                "citation": "Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001 Jan;119(1 Suppl):176S-193S. Review."
            }, 
            {
                "PMID": "15339875", 
                "citation": "McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism. Circulation. 2004 Aug 31;110(9 Suppl 1):I3-9. Review. Erratum in: Circulation. 2005 Jan 25;111(3):378. Circulation. 2004 Dec 14;110(24 Suppl 1):IV33."
            }, 
            {
                "PMID": "17672809", 
                "citation": "Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007 Jul-Aug;13(6):475-86."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ischaemic stroke, haemorrhagic stroke", 
                "measure": "Stroke", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences.", 
                "measure": "Trans Ishaemic Attack (TIA)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences of both ST-Elevated Myocardial Infarction and Non-ST Elevated Myocardial Infarction (STEMI/NSTEMI).", 
                "measure": "Myocardial Infarction", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by number of occurrences.", 
                "measure": "Unstable angina", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Measured by Questionnaire.", 
                "measure": "Quality of life and patient treatment satisfaction over a three year period", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Thrombosis Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Thrombosis Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "May 2014"
    }
}